
Corcept Therapeutics (CORT) Stock Forecast & Price Target
Corcept Therapeutics (CORT) Analyst Ratings
Bulls say
Corcept Therapeutics Inc. demonstrates a strong positive outlook due to its projected risk-adjusted sales, which are anticipated to grow from $171 million in 2026 to a peak of $1.9 billion in 2031. The company’s strategic focus on relacorilant, particularly in the context of increasing market penetration expectations from 20% to 25% for ovarian cancer treatments, underlines its potential for significant revenue growth. Furthermore, the promising survival data from pivotal trials strengthens the probability of approval for relacorilant, indicating a solid foundation for future sales, especially with plans to support its launch with dedicated oncology sales representatives.
Bears say
Corcept Therapeutics has experienced a significant decline in its 12-month price target, dropping from prior estimates of $105 and $145 to $67 and $90 per diluted share, respectively, reflecting a negative outlook primarily due to the Complete Response Letter (CRL) received for relacorilant, which has delayed its launch for treating Cushing’s syndrome. The financial ramifications of this CRL, coupled with anticipated pricing pressures from payors affecting Korlym sales for 2026, further exacerbate concerns regarding the company’s future revenue streams and overall market performance. Additionally, the reliance on multiple valuation methods, such as NPV, EV/sales, and EV/earnings analyses, underscores the economic uncertainty surrounding projected future revenues and profitability through 2034.
This aggregate rating is based on analysts' research of Corcept Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Corcept Therapeutics (CORT) Analyst Forecast & Price Prediction
Start investing in Corcept Therapeutics (CORT)
Order type
Buy in
Order amount
Est. shares
0 shares